The ability to engraft human PBMC or fetal tissue immune cells in the severe combined immunodeficient (SCID) mouse has created a need for characterization of these systems and their application to disease models. We demonstrate that SCID mice reconstituted with PBMC support the growth and differentiation of a restricted set of B cells. Human IgG levels of 1-2 mg/ml (10-20% of normal human serum levels) were routinely achieved in spite of a serum half life of only 12 d. Ig levels peaked around 50 d and Ig production was maintained for > 100 d. The Ig was > 85% IgG though some IgM, IgA, IgD, and even IgE could be detected. However, the human IgG produced in hu-PBL-SCID mice was pauci-clonal when analyzed by isoelectric focusing and by kappa/lambda light chain usage. Using a new polymerase chain reaction based analysis capable of monitoring individual VH family utilization, we found that the engrafted B cells showed skewed and restricted human VH subfamily utilization. These parameters were markedly variable among hu-PBL-SCID mice reconstituted from the same donor cell population at both early (21-50 d) and late stages (> 100 d). Hu-PBL/CVI-SCID mice constructed with cells from patients with common variable immunodeficiency with an in vitro block in terminal B cell differentiation produced human Ig responses that were quantitatively the same as those produced by hu-PBL-SCID mice from normal donors. The hu-PBL-SCID system using PBMC appears to lead to growth and Ig production by a small number of B 
Introduction
Recently, CB. 17 severe combined immunodeficient (homozygous scid/scid, SCID)1 mice have been shown to accept xenogeneic transplants of human lymphoid tissue, specifically pe-1. Abbreviations used in this paper: CVI, common variable immunodeficiency; IEF, isoelectric focusing; PCR, polymerase chain reaction; SCID, severe combined immunodeficient; XLA, X-linked agammaglobulinemia.
ripheral blood mononuclear cells when administered intraperitoneally as well as whole tissue implants of human fetal liver, thymus, and lymph node (1) (2) (3) . SCID mice have also been shown to be permissive to the growth ofhuman hybridoma and whole tissue implants of human lung cancers (4, 5) . When 10-50 X IO6 mature normal human PBMCs are injected intraperitoneally, total human Ig levels of > 1 mg/ml (an order of magnitude below normal human serum concentrations) have been demonstrated. Use of PBMC reconstitution of mice is simple to undertake and could be used to explore many basic and clinical questions relating to immune function. However, the diversity of this response in terms of B cell repertoire and Ig diversity needed to be characterized in order to ascertain the suitability of hu-PBL-SCID mice for modeling of human immune function.
We present evidence on the nature ofthe B cell engraftment and expression of humoral immunity in hu-PBL-SCID mice constructed with cells from normal subjects and from patients with humoral immune defects that have been characterized both in vivo and in vitro. By determining the nature and kinetics of human Ig production in these animals and extending this model human humnoral immunodeficiencies, we have been able to delineate the nature of the humoral reconstitution in the hu-PBL-SCID mouse system.
Methods
Subjects. Informed consent was obtained from normal control, common variable immunodeficiency (CVI), and X-linked agammaglobulinemia (XLA) individuals who served as blood donors for SCID mice reconstitutions. These studies were approved by both the UCLA Human Institutional Review Board and the UCLA Animal Welfare Committee. The normal donors were screened for EBV and HIV status, all were negative for HIV antibodies. Two of the normals shown in Fig. 1 were negative for antibodies to EBV nuclear and viral capid antigens. Individuals with CVI or XLA were not screened for EBV status but were evaluated for HIV status using the HIV specific polymerase chain reaction (PCR) method; all were nonreactive. None ofthe patients had active autoantibody mediated disease, hepatitis, gastrointestinal disease, or lymphoproliferative malignancy. These individuals with CVI or XLA fail to produce spontaneous high rate Ig-secreting lymphoblastoid B cells or measurable serum antibody responses to booster immunization (6) and produce very low levels of Ig in PWM-stimulated cultures. The immunodeficient patients CVI 1-4 and )LA 1-2 are UCLA CIA patients No. 11 1, 1 8, 109, 108, 140, and 141, respectively. All of the individuals with CVI or XLA are maintained on intravenous immunoglobulin but had pretreatment IgG levels of < 2 mg/ml compared with normal adult human levels 6-15 mg/ml. CVI is a heterogeneous group of diseases with a spectrum of intrinsic B cell maturational defects and non-B cell regulatory abnormalities (7) (8) (9) . Individuals with CVI have measurable serum IgG (10-20% of normal levels) but lack high affinity antibodies (10) . The Amplified products were fractionated by agarose electrophoresis using either 2.5%/1.5% Nu-sieve/SeaKem (Food, Materials and Clothing Corp.) in lx TPE buffer (0.08 M Tris-phosphate, 0.008 M EDTA) for N-ras or 1%/1% Nu-sieve/LE agarose gels in lx TAE (0.04 M Trisacetate, 0.002 M EDTA) buffer for LDLr and Ig VDJ. For quantitation, the agarose gels were dried, and autoradiographs were prepared as templates to excise gel slices bearing amplified bands; Cerenkov counts were measured using a scintillation counter (Beckman Instruments, Inc., Palo Alto, CA). Duplicate samples were typically processed, and reported as arithmetic means; the standard errors were < 10%.
Oligonucleotide primers used.
Human Ig VDJ segments, 5'-dAGTGCCAACCGCCTCACAGG (JHKOR, noncoding strand of consensus JH segment) (16); 5'-dTCTGGGGCTGAGGTGAAGAAG (VH I N), 5'-CTGGTG-GAGTCTGGGGGAGGC (VH3L), 5'-dCCAGGACTGGTGAAGCC (VH46N), 5'-dGTGCAGCTGGTGCAGTCT (VH30), and 5'-dGTCCAGTGTGAAGTGCAG (VHCP4), representing various subfamily-specific coding-strand FRI segments (17, 18); 5'-dCCTCC-ACAGTGAGTCTCC (VH5N, coding strand of a VH5 5'-flanking sequence) (17) . Human LDL receptor (exons 14 Statistical analysis. Immunoglobulin measurement data were analyzed using the ELISA Master program for MacIntosh written by Richard Deem, UCLA Department of Medicine. Statistical tests as -noted were performed using the Statworks software package for the MacIntosh personal computer.
Results
Hu-PBL-SCID mice from normals and CVI patients produce high levels of IgG that rapidly turns over. The kinetics and isotype distribution of Ig production by hu-PBL-SCID mice constructed with cells from normals or subjects with humoral immunodeficiency was studied. Mice were reconstituted with 20 x 106 PBMC from normal individuals, four individuals with CVI and two brothers with XLA. IgG, IgM, and IgA could be identified in at least one serum sample of all SCID mice reconstituted with PBMC from both normals and all individuals with CVI. All four IgG subclasses were identifiable in hu-PBL-SCID mice from the four CVI subjects and from the normal donor hu-PBL-SCID mice tested (data not shown). A few normal reconstituted mice additionally produced measurable IgD and/or IgE. No hu-PBL/CVI-SCID mice produced measurable IgE, but a few produced IgD. Fig. 1 shows the mean quantity of human IgG in reconstituted animals over time. Each plotted point represents the mean serum IgG (tg/ml) ofat least six samples (two to four mice/subject and two to three samples/ mouse). IgG levels of 1-3 mg/ml were achieved in all the normal hu-PBL-SCID mice and in hu-PBL/CVI-SCID mice (total of 10) constructed from three CVI subjects that were previously shown to have an in vitro defect in terminal IgG production (CVI [1] [2] [3] . While overall IgG levels fell after day 50, IgG production continued out past day 100 as evidenced by individual mice showing little or no decline in serum IgG level between days 50 and 120. Levels > 1 mg/ml were the norm at day 100. The kinetics ofIgM and IgA production were essentially equivalent to that of IgG, both being readily detectable by day 15 and rising to near maximal levels by 50 d. Maximum serum concentrations of human IgM and IgA were 10-40 tg/ml. Mice producing higher levels of IgG tended toward higher IgM and IgA production.
To verify that active human Ig secreting cells were still present in long term hu-PBL-SCID mice, which maintained high 10000 E CD 1000 100 10 1 levels of human serum Ig, hu-PBL-SCID mouse spleen, and bone marrow cells were cultured for human Ig production Table I. shows that human Ig was spontaneously produced in cultures from both spleen and bone marrow cells. Both IgG and IgM was identified in all cultures in which in vitro Ig production occurred even though the level of human B cells was < I%. Peritoneal lavage cells at these late time points failed to make any human IgG or IgM.
Hu-PBL/CVI-SCID mice constructed with cells from CVI No. 4 showed an early and rapid decrease in Ig production after day 21 although there was persistance of IgG out to 100 d at levels 10-fold lower than in the normal or other CVI reconstituted mice. Hu-PBL/XLA-SCID mice produced with PBMC from two brothers who lacked measurable circulating B cells also showed abnormal reconstitution (Fig. 1) . Sera from hu-PBL/XLA-SCID mice from one subject contained very low levels of Ig at day 15 (10 l g/ml IgG, 0.5 ttg/ml IgM, and 5 Aig/ml IgA) and then decreased below the limit of detection (< 2.5 ng/ml) by day 30 through day 100. This XLA patient's serum contained small amounts of IgA (0.1O mg/ml). The phenomena of IgA production in XLA has been previously reported in a patient who had detectable IgA in his serum yet failed to produce IgA specific plaques to Cowan I, anti-mu, PWM, or T cell replacing factors (21) . Sera from hu-PBL/XLA-SCID mice constructed with cell from the other XLA brother failed to show any human 1g.
The half-life of human IgG in SCID mice was determined. Serum IgG half-life is inversely related to concentration and mice have a far more rapid turnover of IgG than humans (22). Unreconstituted SCID mice were injected intraperitoneally IgG produced in SCID-hu mice showed limited heterogeneity. The light chain representation in IgG and IgM produced by the hu-PBL-SCID and hu-PBL/CVI-SCID mice was used to assess the heterogeneity of Ig production (Table II) . If the humoral reconstitution was truly polyclonal and reflected the normal in vivo situation in humans, the lambda/kappa ratio should be very near 0.5 (34% lambda/66% kappa) seen with normal human sera. In individual hu-PBL-SCID mice, was marked kappa or lambda predominance with ratios from 0.1 1 to 1.56 for IgG and from 0.03 to 5.06 for IgM, compared with the expected ratio of -0.5 (34% lambda/66% kappa) (Table  II) . Skewing was present from the earliest (day 12) to latest (day 155) time of measurement. All but 4 of 36 samples (among 10 animals from 5 donors) fell outside a 0.4-0.6 ratio range. The kappa/lambda ratio varied between mice reconstituted with the same normal donor cells in the same experiment.
To obtain an independent estimate of the heterogeneity of IgG present in the reconstituted SCID-hu mice, sera was isoelectrically focused over a 3-1 0 pH gradient. A pattern ofup to 30 predominant bands was seen with hu-PBL-SCID and hu-PBL/CVI-SCID mice sera (Fig. 2) further suggesting restricted clonality ofthe IgG produced in these animals. In contrast, the normal human donors' sera or pooled human IgG are seen primarily as smears of IgG with rare bands being resolved on this background. The lack of IgG in hu-PBL/CVI-SCID No. 4 or hu-PBL/X-linked agammaglobulinemia/SCID mice sera was also confirmed.
The repertoire of engrafted B cells in hu-PBL-SCID mice shows limited diversity. The degree of human B cell engraftment and clonal diversity was further characterized by quantitative PCR analysis ofgenomic DNA from SCID-hu mice (Fig.  3) . Sense-strand primers were selected to detect subsets ("subfamilies") of various VH gene families, and paired with an antisense-strand JH primer to specifically amplify only fully rearranged VDJ segments (23) (24) (25) (26) . Quantitative PCR reaction conditions were established for a range of 50-250 ng of tem- plate DNA (25) (26) (27) (28) (29) . Because human B cells usually bear only one fully rearranged allele (30) , the abundance of VDJ segments for a particular VH subfamily gene directly corresponds to the abundance of B cells in the population expressing that VH subfamily. In this case, an unbiased hu-PBL-SCID B cell engraftment would be expected to yield the same proportion of rearranged VH subfamilies as in the original human donor material used for engrafting.
At the early phase of reconstitution (days 21-50), human (CD45+) cells were readily detectable in spleen, liver, and lung and present among bone marrow cells (see below). Nonetheless, the VDJ clonal pattern of engrafted B cells during this phase (day 35) was skewed and restricted compared with the donor cell population, and heterogeneous among different tissues (Fig. 3 a) . By day 164, the VH diversity of engrafted cells was further diminished with marked expansion of VH3L B cells (Fig. 3 b) .
Analysis of three replicate animals from an independent long term reconstitution (day 141) is shown in Fig. 3 , c-e. The VDJ clonal pattern was divergent and restricted compared with the donor cell population (note the selective increase in VH46 B cells), and also heterogeneous among the three animals (Fig.  3 c) . The abundance ofhuman B cells in these animals was very low (0.014-0.14%, Fig. 3 d) , despite persistently high levels of in vivo and in vitro production of human IgG (see above). The level of total human cell engraftment was ofgreater magnitude (< 0.5-4%, Fig. 3 e) , but not necessarily concordant from animal to animal with the level of B cell engraftment. Among several sets of long term (> 120 d) hu-PBL-SCID mice, a similar level of CD45+ human cells (< 1-3%) was detected in mononuclear preparations from spleen, lung, liver, and bone marrow.
The level of human cell reconstitution was confirmed in hu-PBL-SCID animals by flow cytometric analysis. CD45+ human cells were generally found in the hu-PBL-SCID mice spleen, liver, and lung (10-70% range in 20 animals), being most readily detectable at days 35-50 with less human cells being present in the bone marrow (1-5%). There was gradual disappearance of these human cells over the ensuing months. Almost all ofthese human CD45+ cells were CD3+ T cells, the analysis of which will be reported elsewhere (Tary-Lehmann et al., in preparation). From a total of 20 animals, the maximum percentage of human cells that were B cells (CD 19 and/or CD20+) was 10%. In the majority of animals, 1% or less of the human cells were B cells at all time points (day 21 to > 100). By day 120, generally < 1% of the liver, lung, spleen, peritoneal lavage, and bone marrow cells recovered stained for CD3, CD4, CD 19, CD20, Leu M3, or CD45. Rare human T cells (< 1% CD3 and either CD4 or CD8 positive) were observed on immunohistologic staining of hu-PBL-SCID splenic tissue. After 120 d, no human B cells were identifiable in either spleen or bone marrow sections despite high levels of in vivo human antibody production in these mice at the time cells were obtained for analysis (Table II) . This data was corroborated by analysis of human repetitive Alu sequences in DNA extracted from the tissues of these same mice and by analysis ofthe LDL receptor/N-ras gene representation (Fig. 3) .
Discussion
The ability to graft human immune tissues into CB. 17 (SCID) mice holds great promise as a system for performing both long term culture and the in vivo manipulation of human cells (1) (2) (3) (4) (5) . We explored the utility of the hu-PBL-SCID mouse model for the investigation of the normal human humoral immunity and for the deficiency state, CVI. Surprisingly, Ig production and diversification in SCID mice given PBMC from three CVI patients previously found incapable of making Ig in vitro ( 11) was indistinguishable from those given normal PBMC. Hu (19) was used as a measure of total human cells. In the latter cases, values were normalized to total recovered genomic DNA using a shared murine/human region of the N-ras gene (20) . Conditions for enzymatic amplifications and oligonucleotide primers have been previously described (19, 20, 25) .
These results raised questions as to the nature of the B cell and supporting cells which provide for the Ig production observed in our hu-PBL-SCID animals. Our results indicate that the hu-PBL-SCID model as employed using PBMC predominantly selects for growth ofsmall numbers ofprecursors ofhigh rate Ig secreting cells. Mature B cells are required; SCID mice given PBMC from two patients with XLA who lack circulating B cells failed to make human Ig, while hu-PBL/CVI-SCID mice constructed from three CVI subjects previously shown to have circulating mIg bearing B cells and an in vitro defect in terminal Ig production (CVI 1-3) had Ig levels indistinguishable from normals.
Thus the question arises as to whether the hu-PBL/CVI-SCID animals represent the induction of a "normal phenotype" in the SCID mouse environment or conversely, whether the normal hu-PBL-SCID mice are, in fact, manifesting a limited humoral immune phenotype/function which can be achieved by both normals and CVI subject cells. The limited and skewed repertoire ofB cells, determined by rearranged VH gene families, strongly supports the latter concept as does the variation in VH family representation between animals from the same donor in the same experiment. It appears that a hu-PBL-SCID mouse represents the engraftment and expression of a small number of B cell clones, clones that appear to be relatively randomly selected even within animals injected from a single donor at one point in time. The limited heterogeneity and light chain predominance of the Ig and the paucity of human B cells observed in the hu-PBL-SCID mice provides additional evidence to support this notion.
Our data suggest that the hu-PBL-SCID model, as presently employed using PBMC, has the limitation of selecting for the growth ofa small number ofpotential precursors ofhigh rate Ig secreting cells present in PBMC. Therefore such cells have only to be present in a limited number to achieve the present level of humoral reconstitution. While it would be theoretically possible to simply use smaller numbers of cells for reconstitution and thereby test the frequency of B cell precursors for engraftment, we and others (2) have noted that graft sizes below 5 X 106 cells leads to overall failure to engraft human cells.
We have observed that it is possible to enhance specific IgG antibody produced in hu-PBL-SCID mice using donor immunization to induce spontaneous antibody (anti-tetanus toxoid) cells (31) in the blood used for SCID mouse reconstitution. This would be equivalent to the use ofblood from patients with primary biliary cirrhosis (32) or systemic lupus erythematosous (33) , known to contain B cells spontaneously producing disease-related antibodies in vitro to engender such an antibody response in hu-PBL-SCID mice. We have characterized such spontaneous antibody producing cells in depth both in vitro and in vivo and have shown they represent a form of triggered memory cell that is capable of transferring both an adoptive antibody response and B cell memory in humans (34) . Thus the present hu-PBL-SCID system using peripheral blood mononuclear cells has important quantitative as well as qualitative limitations that need to be overcome before normal immune function can be evaluated and used to investigate humoral immunodeficiency disorders that are less dramatic than X-linked agammaglobulinemia.
